Topiramate-antagonism of L-glutamate-induced paroxysms in planarians

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 150-153

  Raffa, Robert B ^a   Finno, Kristin E ^a   Tallarida, Christopher S ^a   Rawls, Scott M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Anticonvulsant; Glutamate; Planarian; Seizure; Topiramate

Indexed keywords

GLUTAMIC ACID; TOPIRAMATE;

ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DUGESIA DOROTOCEPHALA; EXPERIMENTAL MODEL; LOCOMOTION; NONHUMAN; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEIZURE; SENSITIVITY ANALYSIS; TURBELLARIA;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FRUCTOSE; GLUTAMIC ACID; ISOMERISM; MOTOR ACTIVITY; PLANARIANS;

EID: 78049287235     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.021     Document Type: Article

References (22)

1. Angehagen M., Ben-Menachem E., Shank R., Ronnback L., Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 2004, 88:320-325.
2. Bazan N.G., Tu B., Rodriguez de Turco E.B. What synaptic lipid signaling tells us about seizure-induced damage and epileptogenesis. Prog. Brain Res. 2002, 135:175-185.
3. Cebrià F., Kudome T., Nakazawa M., Mineta K., Ikeo K., Gojobori T., Agata K. The expression of neural-specific genes reveals the structural and molecular complexity of the planarian central nervous system. Mech. Dev. 2002, 116:199-204.
4. Dalby N.O., Mody I. The process of epileptogenesis: a pathophysiological approach. Curr. Opin. Neurol. 2001, 14:187-192.
5. Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isozymes. Epilepsia 2000, 41(Suppl. 1):S35-S39.
6. Gibbs J.W., Sombati S., DeLorenzo R.J., Coulter D.A. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000, 41(Suppl. 1):S10-S16.
7. Gryder D.S., Rogawski M.A. Selective antagonism of L-GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 2003, 23:7069-7074.
8. Kanda T., Kurokawa M., Tamura S., Nakamura J., Ishii A., Kuwana Y., Serikawa T., Yamada J., Ishihara K., Sasa M. Topiramate reduces abnormally high extracellular levels of L-Glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci. 1996, 59:1607-1616.
9. Lyseng-Williamson K.A., Yang L.P.H. Topiramate: A review of its use in the treatment of epilepsy. Drugs 2007, 67:2231-2256.
10. Maryanoff B.E., Nortey S.O., Gardocki J.F., Shank R.P., Dodgson S.P. Anticonvulsant O-alkyl sulfamates, 23:45-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds. J. Med. Chem. 1987, 30:880-887.
11. Nakamura J., Tamura S., Kanda T., Ishii A., Ishihara K., Serikawa T., Yamada J., Sasa M. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol. 1994, 254:83-89.
12. Nakamura J., Kuwana Y., Yukitoshi N. Target pharmacology of topiramate, a new antiepileptic drug. Nippon Yakurigaku Zasshi 2000, 115:53-57.
13. Pappalardo A., Liberto A., Patti F., Reggio A. Neuroprotective effects of topiramate. Clin. Ter. 2004, 155:75-78.
14. Qian J., Noebels J.L. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res. 2003, 55:225-233.
15. Raffa R.B., Rawls S.M. Planaria: A Model for Drug Action and Abuse 2008, Landes Bioscience, Austin TX.
16. Rawls S.M., Gomez T., Stagliano G.W., Raffa R.B. Measurement of L-glutamate and aspartate in Planaria. J. Pharmacol. Toxicol. Meth. 2006, 53:292-295.
17. Rawls S.M., Thomas T., Adeola M., Patil T., Raymondi N., Poles A., Loo M., Raffa R.B. Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol. Biochem. Behav. 2009, 93:363-367.
18. Shank R.P., Maryanoff B.E. Molecular pharmacodynamics clinical therapeutics and pharmacokinetics of topiramate. CNS Neurosci. Ther. 2008, 14:120-142.
19. Shank R.P., Gardocki J.F., Vaught J.L., Davis C.B., Schupsky J.J., Raffa R.B., Dodgson S.J., Nortey S.O., Maryanoff B.E. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994, 35:450-460.
20. Shank R.P., Doose D.R., Streeter A.J., Bialer M. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res. 2005, 63:103-112.
21. Shank R.P., McComsey D.F., Smith-Swintosky V.L., Maryanoff B.E. Examination of two independent kinetic assays for determining the inhibition of carbonic anhydrases I and II: structure-activity comparison of sulfamates and sulfamides. Chem. Biol. Drug Des. 2006, 68:113-119.
22. Ziemann U. Pharmacology of TMS. Suppl. Clin. Neurophysiol. 2003, 56:226-231.